Get the Stockscreener App
26.92
1.10%
-0.30
After Hours:
26.94
0.02
+0.07%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $26.92, with a volume of 27.80M.
It is down -1.10% in the last 24 hours and down -0.88% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$27.22
Open:
$27.32
24h Volume:
27.80M
Relative Volume:
0.62
Market Cap:
$153.13B
Revenue:
$62.58B
Net Income/Loss:
$7.79B
P/E Ratio:
19.87
EPS:
1.3551
Net Cash Flow:
$9.08B
1W Performance:
-4.94%
1M Performance:
-0.88%
6M Performance:
+8.64%
1Y Performance:
+24.69%
1-Day Range:
$26.77
$27.36
1-Week Range:
$26.77
$28.23
52-Week Range:
$21.28
$28.75
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.92 | 154.84B | 62.58B | 7.79B | 9.08B | 1.3551 |
LLY
Lilly Eli Co
|
939.47 | 853.33B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
238.46 | 581.22B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
207.94 | 375.69B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
204.03 | 317.91B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
121.42 | 303.00B | 64.93B | 18.26B | 12.36B | 7.2751 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | Argus | Hold → Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Underperform |
| Feb-20-26 | Initiated | Barclays | Underweight |
| Feb-12-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer Inc (PFE) Stock Price Quote Today & Current Price Chart - Capital.com
Pfizer’s China Biotech Push Adds New Angle To PFE Valuation Story - Yahoo Finance
Pfizer Options Spot-On: On April 10th, 104.09K Contracts Were Traded, With 2.48 Million Open Interest - Moomoo
Pfizer (PFE) Faces FDA Scrutiny Over Misleading Adcetris Ads - GuruFocus
How Investors Are Reacting To Pfizer (PFE) As RBC Flags Pressure On Key Drug Franchise - simplywall.st
Pfizer Inc. stock (US7170811035): Is its post-COVID pivot strong enough to unlock new upside? - AD HOC NEWS
Pfizer (NYSE: PFE) SVP discloses stock and appreciation right holdings - Stock Titan
Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer? - TradingView
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Atopic Dermatitis (7MM) Drug Market Forecast and Analysis Report 2023-2033: Opportunities Remain for the Treatment of AD, Novel Systemic Therapies Dominate the Late-stage Pipeline - GlobeNewswire Inc.
J.P. Morgan Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $30 - Moomoo
PFIZER INC : Gets a Neutral rating from JP Morgan - marketscreener.com
Hemophilia B Pipeline 2026 Report Highlights Next-Gen Gene Therapies, FDA Advances, and Clinical Momentum Across Novo Nordisk, Pfizer, Sanofi & Emerging Biotechs | DelveInsight - Barchart
Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders - The National Law Review
Pfizer (PFE) Analyst Rating Update: Target Price Lowered to $26 - GuruFocus
Pfizer Invites Shareholders to Virtual 2026 Annual Meeting - National Today
Pfizer shareholders can vote online at April 23 annual meeting - Stock Titan
BCAN Names Ferring Pharmaceuticals and the Astellas/Pfizer Alliance as National Presenting Sponsors of the 2026 Walks to End Bladder Cancer - The Manila Times
Q4 Earnings Highs And Lows: Pfizer (NYSE:PFE) Vs The Rest Of The Branded Pharmaceuticals Stocks - Yahoo Finance
Is Pfizer (PFE) Offering Value After Its 31% One Year Share Price Jump - Yahoo Finance
$1.05 Bn Biopharmaceutical CXO MarketsGlobal Forecast Report 2026-2032: How Leading Pharmas Such as Pfizer, Roche, Novartis, Sanofi, and AstraZeneca Navigate the Evolving Dynamics - Yahoo Finance
Assessing Pfizer (PFE) Valuation After Bearish Analyst Rating And COVID Vaccine Trial Pause - simplywall.st
Pfizer Inc Storebrand Conference: Invest in the Future Call Transcript - GuruFocus
PFIZER INC HUGE TARGET | PFE STOCK NEWS More Tips Here (0G6fMCSiIT) - Mshale
Pfizer Options Spot-On: On April 8th, 90,399 Contracts Were Traded, With 2.45 Million Open Interest - Moomoo
Pfizer Inc. stock rises Wednesday, still underperforms market - MarketWatch
PFE Stock Quote Price and Forecast - CNN
How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results - Yahoo Finance
Diabetes Market: Rapid Increment Driven by Innovation by 2032 – DelveInsight | Eli Lilly and Company, Regor Pharma AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova - Barchart
RBC Capital Reaffirms Their Sell Rating on Pfizer (PFE) - The Globe and Mail
Why Pfizer Stock Tumbled on Tuesday - AOL.com
Pfizer Reshapes Portfolio With Seagen And Metsera As COVID Winds Shift - Yahoo Finance
Comirnaty: Pfizer-BioNTech COVID-19 Vaccine Explained - AD HOC NEWS
Belgian Court Ruling Extends Pfizer Covid Cash Flow And Legal Questions - simplywall.st
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Major biotech company shutting down South San Francisco office - KRON4
Biotech giant abandoning South San Francisco research site - SFGATE
Pfizer Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Pfizer Options Spot-On: On April 7th, 158.61K Contracts Were Traded, With 2.38 Million Open Interest - Moomoo
PFIZER INC (PFE.SW) Q1 FY2025 earnings call transcript - Yahoo Finance
Pfizer stock slides 2.52% as company highlights CDK research progress in metastatic breast cancer - Traders Union
Pfizer (PFE) Faces Bearish Sentiment Among Options Traders - GuruFocus
Pfizer Inc. (NYSE:PFE) Market Action Tied To S&P 500 Index Movement - Kalkine Media
Pfizer’s New Phase 1 PF-07328948 Study Signals Ongoing Pipeline Investment - TipRanks
Pfizer Targets Advanced Kidney Cancer With New PF-08634404 Trial: What Investors Should Know - TipRanks
What is behind Pfizer stock's recent drop in value today - Traders Union
Messenger RNA (mRNA) Market Projected to Reach $20.99 Billion by 2035Moderna, Pfizer, and Others Propel mRNA Expansion into New Therapeutic Areas - Yahoo Finance
Prediction: In 5 Years, You'll Wish You Bought Pfizer Stock Today - The Globe and Mail
Eosinophilic Esophagitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Regeneron Pharma, Sanofi, Bristol-Myers Squibb, Ellodi Pharma, AstraZeneca, Allakos, EsoCap, Pfizer - Barchart
RBC Capital reiterates Pfizer stock Underperform rating on product headwinds - Investing.com
RBC Capital Maintains Pfizer(PFE.US) With Sell Rating, Maintains Target Price $25 - Moomoo
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
2.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):